meta_pixel
Tapesearch Logo
Log in
Science Talk

COVID-19 Vaccine Ethics: Who Gets It First and Other Issues

Science Talk

Scientific American

Science

4.2644 Ratings

🗓️ 6 August 2020

⏱️ 25 minutes

🧾️ Download transcript

Summary

Contributing editor W. Wayt Gibbs spoke with Arthur Caplan, head of the NYU Grossman School of Medicine’s division of medical ethics, about some of the ethical issues that researchers have to consider in testing and distributing vaccines against COVID-19. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

There are some things you should always check, like the hygiene rating on your local takeaway,

0:06.2

the setting on your razor, and whether the party actually is fancy dress.

0:11.1

The other thing you should check is your Experian credit report, especially if you're looking to borrow money.

0:17.2

It lets you understand what lenders see, so you can increase your chances of getting the best deals.

0:22.8

It's dead easy to check it and completely free.

0:26.6

See it in seconds. Download the Experian app today.

0:30.9

Welcome to another in our series of coronavirus episodes of Scientific American Science Talk posted on August 6th, 2020.

0:39.4

I'm Steve Murksky.

0:40.9

In this episode, we hear again from contributing editor W.A. Gibbs.

0:45.9

As part of a national Press Foundation Fellowship he's doing,

0:49.3

Gibbs spoke on July 30th with Arthur Kaplan,

0:52.5

head of the New York University School of Medicine's

0:55.0

Division of Medical Ethics, about some of the ethical issues that researchers have to consider

1:00.3

in testing experimental vaccines against COVID-19. Questions like, does participating in a vaccine

1:07.1

trial mean you cannot receive an experimental medicine for COVID if you do get sick,

1:12.6

and would it be ethical to test the vaccine in prisons where inmates face very high risks

1:18.1

of coronavirus infection? Gibbs and Kaplan also discussed ethical questions will face when a vaccine

1:24.7

eventually is approved for use, such as whether there's a

1:28.4

moral argument for strong-arming a drug company into releasing its vaccine technology into the

1:34.1

public domain. Also in this episode, we'll hear a sponsored segment from AstraZeneca, and we also

1:40.1

have a short report from Scott Hirschberger on how our wacky brains think about round numbers

1:46.1

versus specific numbers when considering how good a disease treatment may be. But first,

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Scientific American, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Scientific American and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.